Lawsuit Updates

This page tracks NAION-related lawsuit updates, including MDL 3163 context, court developments, and connected source summaries.

GLP-1 receptor agonists, NAION vision-loss questions, and semaglutide safety updates
EMA PRAC (June 6, 2025): recommended listing NAION as a very rare side effect (up to 1 in 10,000) for semaglutide medicines
MDL No. 3163 centralized in the Eastern District of Pennsylvania on Dec 15, 2025; JPML report dated Apr 1, 2026 lists 73 pending actions

Medical research

Public studies continue to assess GLP-1 and NAION risk signals

Retrospective studies in 2024 and 2025 raised NAION risk questions in semaglutide users, but findings remain mixed. Read this as evolving medical context before drawing individual conclusions.

Safety updates

EMA PRAC recommended a very-rare NAION label update for semaglutide

On June 6, 2025, EMA PRAC recommended listing NAION as a very rare side effect for Ozempic, Rybelsus, and Wegovy. Safety labels can continue changing as evidence updates.

Public litigation

MDL 3163 remains active in federal court tracking

JPML centralized these federal GLP-1 and NAION cases in the Eastern District of Pennsylvania on Dec 15, 2025. The Apr 1, 2026 pending report lists 73 pending actions.

Related pages

Continue with these pages

These related pages help visitors continue reading and compare nearby topics without losing the main page context.

What Is NAION?

This page explains what NAION is, why sudden vision-loss symptoms matter, and which public background points visitors usually review first.

Visit page

GLP-1 Drugs and NAION

Review how GLP-1 receptor agonists such as Ozempic, Wegovy, and related medicines appear in public NAION discussions, studies, and safety updates.

Visit page

NAION Symptoms and Diagnosis

This page outlines common NAION-related symptom descriptions and diagnosis context so visitors can compare public information with their own timeline.

Visit page

Who May Qualify

Use this page for an initial relevance check based on medication history, symptom timing, and medical context before deciding on the next…

Visit page

Free Case Review for NAION Claims

This page connects NAION-focused visitors to the site’s direct case-review path and next-step guidance.

Visit page

How to use this NAION lawsuit updates page

Use this page to follow public court milestones, MDL scheduling context, and related regulatory summaries in one place.

The goal is to help you read first, then decide whether your own timeline may warrant a free case review.

Track MDL 3163 case-management updates and federal court status.
Compare litigation movement with EMA and FDA safety-context summaries.
Keep the first step simple: read updates first, then decide whether to contact.

Current federal litigation status (last verified April 2026)

JPML transfer materials filed on December 15, 2025 established MDL No. 3163 in the Eastern District of Pennsylvania before Judge Karen S. Marston for federal GLP-1 and NAION vision-loss lawsuits.

In the JPML pending-MDL report dated April 1, 2026, MDL 3163 remains listed as pending with 73 actions.

Centralization does not determine individual outcomes; it organizes federal pretrial handling.
Action counts and schedules can change as filings are transferred or resolved.
The most useful reading order is court status first, then eligibility context.

Related source summaries and next step

For broader context, this site also summarizes the MDL 3163 court page, JPML monthly pending report, and FDA compounded GLP-1 warning-letter release.

These linked pages keep official-source reading inside the site so you can compare updates before deciding whether to submit a short free case review.